Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORCEPT-E 1/35 21 vs ESTROSTEP 21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.
Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
Prevention of pregnancy,Oral contraceptive
Prevention of pregnancy,Treatment of moderate acne vulgaris in females >= 15 years of age who have achieved menarche, are not pregnant, and desire oral contraception
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.
One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13-27 hours), consistent with once-daily dosing; norethindrone: terminal half-life approximately 7.6 hours (range 5-12 hours), permitting steady-state within 5 days.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours (terminal). Steady-state achieved within 3-5 days.
Ethinyl estradiol: primarily metabolized by CYP3A4; norethindrone: primarily metabolized by CYP3A4 and reduction.
Ethinyl estradiol is metabolized primarily via CYP3A4 and undergoes glucuronidation and sulfation. Norethindrone acetate is deacetylated to norethindrone, which is metabolized by CYP3A4 and other CYP enzymes, and undergoes reduction and glucuronidation.
Renal: 50-60% as metabolites (primarily ethinyl estradiol glucuronide and norethindrone metabolites); fecal: 20-30% via biliary elimination; unchanged drug: <5%.
Biliary/fecal (40-50% as metabolites) and renal (30-40% as glucuronide and sulfate conjugates)
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 61-65% bound to albumin and SHBG.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 95-97% bound to albumin and SHBG.
Ethinyl estradiol: 2.3-4.3 L/kg, indicating extensive tissue distribution; norethindrone: 3.4-4.2 L/kg, consistent with distribution beyond plasma volume.
Ethinyl estradiol: 2.5-4.5 L/kg; norethindrone: 3.5-5.5 L/kg. Indicates extensive tissue distribution.
Oral: ethinyl estradiol 40-45% (first-pass metabolism); norethindrone 60-65% (first-pass metabolism).
Ethinyl estradiol: 38-48% (oral, first-pass metabolism); norethindrone acetate: 50-70% (oral, deacetylation to norethindrone).
No dosage adjustment required for mild to moderate renal impairment. Avoid use in severe renal impairment or end-stage renal disease due to potential fluid retention and hormonal metabolism alterations.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Contraindicated in acute or chronic hepatic impairment (Child-Pugh class A, B, or C) due to impaired steroid hormone clearance and increased risk of adverse effects.
Contraindicated in acute hepatitis, severe cirrhosis, benign or malignant liver tumors, or Child-Pugh class C cirrhosis. Use with caution in Child-Pugh class A or B; consider alternative therapy.
Not indicated for use before menarche. For adolescent females, same dosing as adults: one tablet daily for 21 days, then 7 days off. Weight-based adjustments not required; use standard dosing if post-menarche.
Not indicated for use before menarche. Post-menarche: same dosing as adults; use lowest effective dose for shortest duration.
Not indicated for use after menopause. No specific dosing adjustments studied; avoid use in elderly due to increased risk of thromboembolic events and lack of benefit for postmenopausal contraception.
Not indicated for postmenopausal women; no established dosing in elderly. Consider alternative therapies as necessary.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (especially in women over 35). Women should not smoke while using this product.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women > 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders,Cardiovascular disease risk,Carcinoma of breast and reproductive organs,Hepatic neoplasia,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid effects,Headache,Bleeding irregularities,Ectopic pregnancy,Depression
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction), especially in smokers and women over 35,Hepatic neoplasia (benign and malignant) reported,Hypertension and gallbladder disease,Carbohydrate and lipid effects; monitor in diabetic patients,Ocular lesions (e.g., retinal thrombosis); discontinue if unexplained vision loss or proptosis occurs,Hereditary angioedema exacerbation,Chloasma; avoid sun exposure,Menstrual irregularities (e.g., breakthrough bleeding, amenorrhea),Depression; discontinue if severe
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebral vascular or coronary artery disease,Known or suspected breast cancer,Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Current or past history of ischemic heart disease,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Known hypercoagulopathies,Uncontrolled hypertension,Smoking in women over 35 years,Severe renal disease
Thrombophlebitis, thromboembolic disorders, or history thereof (e.g., deep vein thrombosis, pulmonary embolism),Cerebrovascular disease (e.g., stroke, TIA),Coronary artery disease (e.g., myocardial infarction, angina),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Benign or malignant liver tumors,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35 years of age
No specific food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically significant. Maintain consistent dietary habits to avoid gastrointestinal upset.
No specific food interactions. Grapefruit juice may increase estrogen exposure (mild effect). Maintain consistent timing with meals to reduce nausea if needed. Avoid alcohol if liver function is compromised.
Epidemiological studies have not revealed an increased risk of birth defects in infants born to women who used oral contraceptives (OCs) before pregnancy or inadvertently during early pregnancy. However, OCs are contraindicated during pregnancy due to potential hormonal effects on the developing fetus. Use of OCs during the second and third trimesters is not associated with teratogenicity, but has been linked to an increased risk of fetal outcomes such as low birth weight and possibly congenital anomalies in some studies, though not consistently. The overall risk is considered low, but OCs should be discontinued if pregnancy is confirmed.
Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and neural tube defects. Second and third trimesters: associated with fetal genital abnormalities, feminization of male fetuses, and potential long-term reproductive effects. Use in early pregnancy for emergency contraception is not recommended due to potential risks.
Small amounts of oral contraceptive steroids have been identified in breast milk, with an estimated infant dose of 0.1% to 1% of the maternal daily dose. The milk-to-plasma ratio (M/P) for ethinyl estradiol is approximately 0.42 under steady-state conditions. Use of combined oral contraceptives during lactation may reduce milk production and breast milk quality, especially when initiated soon after delivery. Therefore, use of combined OCs is generally not recommended during breastfeeding, particularly in the first 6 months postpartum. Progestin-only preparations are preferred.
Estrostep 21 is excreted in breast milk in small amounts; ethinyl estradiol M/P ratio approximately 0.1; norethindrone M/P ratio ~0.5. May reduce milk production and quality, especially in early lactation. Use generally avoided during breastfeeding; consider progestin-only alternatives.
Norcept-E 1/35 21 is contraindicated during pregnancy and should not be used. Therefore, no dosing adjustments are applicable; the drug should be discontinued immediately if pregnancy occurs. No pharmacokinetic studies have been conducted in pregnant women, but physiological changes (e.g., increased volume of distribution, increased renal clearance) would occur if taken, but no dose adjustment is recommended because use is contraindicated.
Estrostep 21 is contraindicated in pregnancy; no dose adjustments recommended as use is avoided. Pharmacokinetic changes during pregnancy (increased hepatic metabolism, volume of distribution) would require dose adjustment if used, but due to risks, alternative therapy is indicated.
This product contains norethindrone 1 mg and ethinyl estradiol 35 mcg. It is a monophasic oral contraceptive. Counsel patients to take at the same time daily. If a dose is missed, follow standard missed pill guidelines. Use additional non-hormonal contraception during first 7 days of initial cycle. Avoid use in smokers over 35 years of age due to increased thromboembolic risk. Monitor for signs of thrombosis, hypertension, and mood changes. May reduce milk supply in breastfeeding women.
ESTROSTEP 21 is a monophasic oral contraceptive containing norethindrone acetate and ethinyl estradiol. Due to its low estrogen dose (20 mcg), it may be associated with more breakthrough bleeding compared to higher-dose pills. It is indicated for contraception and may be used for acne treatment. The 21-day regimen requires a 7-day hormone-free interval. Counsel patients that smoking increases the risk of serious cardiovascular adverse effects; avoid in women over 35 who smoke.
Take one pill daily at the same time each day, even if you do not have sex.,If you miss a pill, refer to the patient leaflet or ask your healthcare provider for instructions.,Use a backup method (like condoms) for the first 7 days when starting the pill.,Do not smoke cigarettes while taking this medication, especially if you are over 35.,Seek medical help immediately if you experience severe leg pain, chest pain, shortness of breath, severe headache, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.
Take one tablet daily at the same time each day for 21 days, then no pills for 7 days.,If you miss a dose, follow the package instructions; use backup contraception if missed more than one tablet.,Do not smoke while taking this medication; smoking increases risk of blood clots, stroke, and heart attack, especially if over 35.,Common side effects include spotting, nausea, breast tenderness, and headache; these often improve after a few cycles.,Seek emergency care if you have signs of a blood clot: sudden leg pain, chest pain, shortness of breath, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Take missed pills as soon as remembered; do not take more than two tablets in one day.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORCEPT-E 1/35 21 vs ESTROSTEP 21, answered by our medical review team.
NORCEPT-E 1/35 21 is a Combined Oral Contraceptive that works by Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.. ESTROSTEP 21 is a Combined Oral Contraceptive that works by Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORCEPT-E 1/35 21 and ESTROSTEP 21 depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORCEPT-E 1/35 21 is: One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.. The standard adult dose of ESTROSTEP 21 is: One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORCEPT-E 1/35 21 and ESTROSTEP 21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORCEPT-E 1/35 21 is classified as Category C. Epidemiological studies have not revealed an increased risk of birth defects in infants born to women who used oral contraceptives (OCs) before pregnancy or inadvertently during ea. ESTROSTEP 21 is classified as Category C. Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.